ARHGAP39: A Potential Drug Target and Biomarker for G protein-Coupled Receptors

Target Name: ARHGAP39

NCBI ID: G80728

ARHGAP39

ARHGAP39: A Potential Drug Target and Biomarker for G protein-Coupled Receptors

G protein-coupled receptors (GPCRs) are a family of transmembrane proteins that play a crucial role in cellular signaling. They are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. GPCRs are known for their high degree of genetics and molecular diversity, which makes them an attractive target for the development of new drugs and biomarkers. In this article, we discuss ARHGAP39, a GPCR-associated protein that has been identified as a potential drug target and biomarker.

ARHGAP39 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is a part of the Rho GTPase-activating protein (RhoA) family, which is known for its role in cell signaling and cytoskeletal organization . RhoA is a protein that plays a central role in regulating the cytoskeleton and cell signaling. It contains a GTPase activity that is responsible for regulating the levels of intracellular signaling molecules, such as neurotransmitters and hormones.

ARHGAP39 has been shown to be involved in various cellular processes, including cell signaling, cytoskeletal organization, and neurotransmission. It has been shown to interact with various GPCRs, including GPCR1, GPCR2, and GPCR3. GPCR1 and GPCR2 are known as the visual pigment receptors Body 1 and 2, respectively, and are involved in vision. GPCR3 is known as the sensorineural epithelial growth factor-2 (SAX-2), and is involved in sensory perception.

ARHGAP39 has been shown to play a role in regulating the activity of GPCR1 and GPCR2. It has been shown to inhibit the activity of GPCR1 and GPCR2, which is thought to enhance the activity of other GPCR signaling pathways. ARHGAP39 has also been shown to regulate the level of neurotransmitters, such as dopamine and serotonin, in various tissues.

In addition to its role in GPCR signaling, ARHGAP39 has also been shown to play a role in the regulation of cytoskeletal organization. It has been shown to interact with the protein Co-regulatory complex (CoRCS), which is responsible for regulating the stability of the cytoskeleton. CoRCS is a complex that contains multiple proteins that interact with each other to regulate the stability of microtubules, which are important for cytoskeletal organization.

ARHGAP39 has also been shown to play a role in the regulation of cell signaling pathways that are involved in the development and maintenance of tissues. It has been shown to interact with the protein p180, which is involved in the regulation of cell growth, differentiation, and survival. p180 is a member of the p180GTPase family, which is involved in the regulation of cell signaling pathways.

In conclusion, ARHGAP39 is a protein that has been shown to play a role in various cellular processes, including GPCR signaling, cytoskeletal organization, and cell signaling pathways. Its function as a potential drug target and biomarker makes it an attractive target for the development of new drugs that can modulate GPCR signaling pathways. Further research is needed to fully understand the role of ARHGAP39 in cellular signaling and its potential as a drug target and biomarker.

Protein Name: Rho GTPase Activating Protein 39

The "ARHGAP39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets